Skip to content
D |
H |
B |
W |
H |
A |
X |
W |
N |
C |
C |
E |
O |
I |
P |
N |
I |
R |
M |
I |
D |
W |
T |
U |
B |
C |
S |
E |
D |
H |
T |
A |
W |
Y |
T |
B |
O |
O |
R |
M |
Q |
Q |
M |
H |
Q |
P |
M |
L |
G |
E |
F |
F |
U |
K |
A |
I |
O |
L |
D |
E |
B |
V |
J |
Y |
V |
J |
A |
Q |
P |
Y |
N |
H |
T |
V |
F |
O |
T |
D |
Q |
V |
K |
D |
C |
N |
X |
T |
O |
N |
M |
E |
I |
I |
Q |
I |
B |
E |
C |
V |
N |
H |
K |
C |
K |
I |
Q |
V |
W |
M |
D |
P |
Y |
B |
D |
Y |
E |
U |
P |
S |
Q |
S |
C |
P |
O |
J |
Y |
B |
V |
X |
D |
W |
T |
U |
J |
A |
Y |
C |
P |
W |
L |
N |
K |
A |
Y |
L |
O |
V |
M |
K |
V |
H |
H |
N |
N |
Q |
R |
U |
A |
C |
L |
M |
B |
D |
W |
Y |
B |
D |
O |
H |
P |
W |
E |
F |
B |
O |
A |
B |
T |
C |
L |
V |
I |
K |
T |
M |
Y |
B |
C |
T |
I |
X |
J |
P |
O |
J |
H |
R |
A |
K |
I |
G |
A |
L |
B |
Q |
D |
A |
B |
C |
X |
F |
O |
B |
A |
R |
D |
L |
D |
V |
H |
T |
M |
O |
M |
M |
Q |
I |
U |
C |
R |
A |
I |
X |
C |
R |
W |
N |
J |
U |
I |
W |
E |
R |
J |
B |
Q |
U |
C |
Y |
C |
E |
B |
P |
T |
A |
I |
X |
E |
V |
O |
N |
Q |
R |
M |
I |
M |
R |
S |
K |
G |
N |
P |
C |
B |
S |
W |
N |
B |
B |
Q |
G |
I |
L |
U |
W |
U |
V |
Q |
A |
D |
K |
I |
X |
A |
L |
Y |
Q |
S |
A |
P |
Q |
D |
X |
Q |
I |
R |
D |
A |
F |
O |
D |
Q |
X |
G |
N |
S |
S |
B |
H |
O |
L |
T |
Y |
O |
H |
D |
G |
O |
X |
T |
T |
J |
U |
O |
P |
L |
E |
D |
K |
C |
H |
U |
Q |
B |
G |
E |
B |
J |
F |
E |
O |
K |
N |
L |
G |
P |
R |
D |
N |
C |
U |
Y |
L |
T |
V |
I |
J |
C |
L |
R |
F |
N |
A |
D |
I |
I |
E |
K |
U |
H |
P |
H |
A |
H |
O |
J |
D |
B |
C |
L |
X |
S |
L |
X |
Y |
R |
D |
P |
E |
K |
X |
M |
J |
W |
C |
W |
B |
I |
C |
I |
Y |
T |
E |
E |
M |
N |
Q |
P |
V |
J |
J |
C |
N |
A |
H |
G |
U |
V |
U |
K |
N |
U |
X |
B |
W |
J |
P |
R |
E |
R |
R |
V |
Clues
- 3rd Line treatment for chronic heart faulure (7, 10)
- describe the rate control drugs someone with AF might be on (7, 3, 1, 7)
- treatment for afro-caribbean patients w/ other co-morbidities with hypertension (11, 4)
- what should you not use DOACs with (8)
Comments
No comments have yet been made